These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

216 related articles for article (PubMed ID: 33941550)

  • 21. Patterns of glycaemic control in patients with type 2 diabetes mellitus initiating second-line therapy after metformin monotherapy: Retrospective data for 10 256 individuals from the United Kingdom and Germany.
    Khunti K; Godec TR; Medina J; Garcia-Alvarez L; Hiller J; Gomes MB; Cid-Ruzafa J; Charbonnel B; Fenici P; Hammar N; Hashigami K; Kosiborod M; Nicolucci A; Shestakova MV; Ji L; Pocock S
    Diabetes Obes Metab; 2018 Feb; 20(2):389-399. PubMed ID: 28817227
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Intensive Treatment and Severe Hypoglycemia Among Adults With Type 2 Diabetes.
    McCoy RG; Lipska KJ; Yao X; Ross JS; Montori VM; Shah ND
    JAMA Intern Med; 2016 Jul; 176(7):969-78. PubMed ID: 27273792
    [TBL] [Abstract][Full Text] [Related]  

  • 23. What are the factors associated with long-term glycaemic control in patients with type 2 diabetes and elevated glycated haemoglobin (≥7.0%) at initiation of second-line therapy? Results from the DISCOVER study.
    Bonnet F; Chen H; Cooper A; Gomes MB; Ji L; Leigh P; Ramirez L; Shestakova MV; Shimomura I; Siddiqui A; Tang F; Vora J; Watada H; Khunti K
    Diabetes Obes Metab; 2021 Oct; 23(10):2336-2343. PubMed ID: 34212481
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Influence of Fasting Glucose Levels on Achieving Glycemic Target in Individuals with Type 2 Diabetes: a Post Hoc Analysis.
    Ma J; Lei M; Li Y; Zhang X; Cui N; Yang W
    Adv Ther; 2020 Sep; 37(9):3816-3826. PubMed ID: 32671687
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Beyond HbA1c.
    Bloomgarden Z
    J Diabetes; 2017 Dec; 9(12):1052-1053. PubMed ID: 28792665
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Towards an improved global understanding of treatment and outcomes in people with type 2 diabetes: Rationale and methods of the DISCOVER observational study program.
    Ji L; Bonnet F; Charbonnel B; Gomes MB; Kosiborod M; Khunti K; Nicolucci A; Pocock S; Rathmann W; Shestakova MV; Shimomura I; Watada H; Fenici P; Hammar N; Hashigami K; Macaraeg G; Surmont F; Medina J
    J Diabetes Complications; 2017 Jul; 31(7):1188-1196. PubMed ID: 28499961
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Changes in HbA1c and weight, and treatment persistence, over the 18 months following initiation of second-line therapy in patients with type 2 diabetes: results from the United Kingdom Clinical Practice Research Datalink.
    Wilding J; Godec T; Khunti K; Pocock S; Fox R; Smeeth L; Clauson P; Fenici P; Hammar N; Medina J
    BMC Med; 2018 Jul; 16(1):116. PubMed ID: 30008267
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Predictors of HbA1c levels in patients initiating metformin.
    Martono DP; Hak E; Lambers Heerspink H; Wilffert B; Denig P
    Curr Med Res Opin; 2016 Dec; 32(12):2021-2028. PubMed ID: 27552675
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effect of patients' risks and preferences on health gains with plasma glucose level lowering in type 2 diabetes mellitus.
    Vijan S; Sussman JB; Yudkin JS; Hayward RA
    JAMA Intern Med; 2014 Aug; 174(8):1227-34. PubMed ID: 24979148
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Assessing hypoglycemia frequency using flash glucose monitoring in older Japanese patients with type 2 diabetes receiving oral hypoglycemic agents.
    Abe H; Shikuma J; Suwanai H; Sano K; Okumura T; Kan K; Takahashi T; Miwa T; Suzuki R; Odawara M
    Geriatr Gerontol Int; 2019 Oct; 19(10):1030-1035. PubMed ID: 31486247
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Switching "Real-World" Diabetes Patients to Degludec from Other Basal Insulins Provides Different Clinical Benefits According to Their Baseline Glycemic Control.
    Tentolouris N; Knudsen ST; Lapolla A; Wolden ML; Haldrup S; Schultes B
    Adv Ther; 2019 May; 36(5):1201-1210. PubMed ID: 30879256
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Socioeconomic factors associated with hypoglycaemia in patients starting second-line glucose-lowering therapy: The DISCOVER study.
    Rathmann W; Charbonnel B; Gomes MB; Hammar N; Khunti K; Kosiborod M; Kuss O; Shestakova MV; Watada H; Shimomura I; Tang F; Cid-Ruzafa J; Chen H; Fenici P; Surmont F; Ji L;
    Diabetes Res Clin Pract; 2020 Jul; 165():108250. PubMed ID: 32531326
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Associations between second-line glucose-lowering combination therapies with metformin and HbA1c, body weight, quality of life, hypoglycaemic events and glucose-lowering treatment intensification: The DISCOVER study.
    Khunti K; Charbonnel B; Cooper A; Gomes MB; Ji L; Leigh P; Nicolucci A; Rathmann W; Shestakova MV; Siddiqui A; Tang F; Watada H; Chen H;
    Diabetes Obes Metab; 2021 Aug; 23(8):1823-1833. PubMed ID: 33852202
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Risk Factors for Nocturnal Hypoglycemia in Insulin-treated Patients With Type 2 Diabetes: A Secondary Analysis of Observational Data Derived From an Integrated Clinical Trial Database.
    Bae JP; Duan R; Fu H; Hoogwerf BJ
    Clin Ther; 2017 Sep; 39(9):1790-1798.e7. PubMed ID: 28781218
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Adherence to the American Diabetes Association's Glycemic Goals in the Treatment of Diabetes Among Older Americans, 2001-2018.
    Le P; Ayers G; Misra-Hebert AD; Herzig SJ; Herman WH; Shaker VA; Rothberg MB
    Diabetes Care; 2022 May; 45(5):1107-1115. PubMed ID: 35076695
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Treatment patterns and glycated haemoglobin levels over 36 months in individuals with type 2 diabetes initiating second-line glucose-lowering therapy: The global DISCOVER study.
    Charbonnel BH; Chen H; Cid-Ruzafa J; Cooper A; Fenici P; Gomes MB; Saraiva GL; Medina J; Nicolucci A; Shestakova MV; Shimomura I; Surmont F; Tang F; Vora J; Watada H; Khunti K;
    Diabetes Obes Metab; 2023 Jan; 25(1):46-55. PubMed ID: 36111434
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Real-world impact on monthly glucose-lowering medication cost, HbA
    Rose TN; Jacobs ML; Reid DJ; Bouwmeester CJ; Conley MP; Fatehi B; Matta TM; Barr JT
    J Am Pharm Assoc (2003); 2020; 60(1):31-38.e1. PubMed ID: 31611005
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Influence of baseline glycemia on outcomes with insulin glargine use in patients uncontrolled on oral agents.
    Banerji MA; Baron MA; Gao L; Blonde L
    Postgrad Med; 2014 May; 126(3):111-25. PubMed ID: 24918797
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Glycemic control and safety in Chinese patients with type 2 diabetes mellitus who switched from premixed insulin to insulin glargine plus oral antidiabetics: a large, prospective, observational study.
    Zhang B; Zhao J; Yang W;
    Diabetes Metab Res Rev; 2017 Mar; 33(3):. PubMed ID: 27667797
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Evaluation of effectiveness of treatment paradigm for newly diagnosed type 2 diabetes patients in Chin: A nationwide prospective cohort study.
    Cai X; Hu D; Pan C; Li G; Lu J; Ji Q; Su B; Tian H; Qu S; Weng J; Zhang D; Xu J; Ji L
    J Diabetes Investig; 2020 Jan; 11(1):151-161. PubMed ID: 31161658
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.